Drug profile

The FDA adverse-event record for Distemper-Adeno-Parvo-4Way Lepto

29 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Distemper-Adeno-Parvo-4Way Lepto. Species, reactions, and outcomes follow.

#1472 of 2,679
by report volume (all drugs)
29
adverse-event reports
6.9%
death-coded share
Dog
most-reported species

Corpus placement

According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Distemper-Adeno-Parvo-4Way Lepto ranks #1463 of 2679 by total reports (29). Death-coded-share rank requires at least 50 reports. National dual: Milbemycin Oxime + Spinosad is #1 of 2679 drugs by total adverse-event reports (149,624) at death-coded-share rank 965 of 1130 drugs with at least 50 reports (2.3%); separately, Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) is #1 highest death-coded share at 97.8% (report rank #821).

149,624
Milbemycin Oxime + Spinosad reports (#1)
97.8%
Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) death share (#1)
#1463
This drug, reports of 2679

Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Distemper-Adeno-Parvo-4Way Lepto has 29 reports now versus 29 in that prior snapshot: 0 the same number of (0.0%).

Report change
+0
Death-coded reports
+0
Death-coded share
−0.0 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Distemper-Adeno-Parvo-4Way Lepto changes

Signature read: death-coded report count at 2 is the most distinctive stamp on Distemper-Adeno-Parvo-4Way Lepto's FDA AER row.

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
29
Total Reports
2
Deaths Reported
6.9%
Death-coded share of reports

Active Ingredients

Distemper-Adeno-Parvo-4Way Lepto

Administration Routes

SubcutaneousUnknown

Species Affected

Dog 29

Most Affected Breeds

Chihuahua 4
Boxer (German Boxer) 3
Retriever - Golden 2
Retriever - Labrador 2
Dachshund - Standard Smooth-haired 1
Terrier - Bull - American Pit 1
Komondor 1
Spaniel (unspecified) 1
Shih Tzu 1
Shepherd Dog - German 1

Most Reported Reactions

Vomiting 16
Anaphylaxis 11
Facial swelling (see also 'Skin') 6
Hives (see also 'Skin') 5
Lethargy (see also Central nervous system depression in 'Neurological') 5
Diarrhoea 4
Lateral recumbency 4
Laboured breathing 3
Bloody diarrhoea 3
Anorexia 3
Vocalisation 2
Collapse NOS (see also 'Cardio-vascular' and 'Neurological disorders') 2

Outcome Breakdown

Ongoing
17 (58.6%)
Recovered/Normal
10 (34.5%)
Died
1 (3.4%)
Euthanized
1 (3.4%)

Distemper-Adeno-Parvo-4Way Lepto Adverse Event Insights

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

What to do with this drug

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Distemper-Adeno-Parvo-4Way Lepto (#1472 of 2,679 by report volume); death-coded 6.9%. PlainBreed drug row · death-coded report count stamp 2 · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →